Ranbaxy Laboratories close to claiming 50% share of atorvastatin market in 6-month exclusivity period Ranbaxy Laboratories looks set to garner more than 50% share in the atorvastatin market in the US, overtaking the combined market share of Pfizer's Lipitor as well as its generic partner in the country, during the crucial six-month exclusive marketing period. It will beat the analyst estimates about the performance of its low-cost version of Lipitor, the anti-cholesterol blockbuster drug.
India's largest drugmaker had increased its market share in the US atorvastatin market to 45% on March 16, from 41% in February 3, according to drug market research firm IMS Health's latest data. Atorvastatin is the chemical entity used for making Lipitor and its copycat versions.
In the first week of its launch in early December, Watson, which had launched the drug a day ahead of Ranbaxy, had captured about 80% of the generic atorvastatin drug market. But it quickly ceded market share to the Indian firm. At present, Watson share is in the early 20s with Pfizer accounting for the rest.